Market Overview

Theragenics Makes No Comment on Market Activity from Dec. 20th, 2012

Related TGX
Theragenics Reports End of Go-Shop Period, Says No Parties Submitted Proposal to Buy
UPDATE: Juniper to Buy Theragenics at $2.20/Share in Cash

Theragenics Corporation (NYSE: TGX), a medical device company serving the surgical products and prostate cancer treatment markets, announced today that in view of the market activity in the Company's stock on Thursday, December 20, 2012, the New York Stock Exchange contacted the Company on December 24, 2012, in accordance with the Exchange's usual practice. The Company stated that its policy is not to comment on market activity.

Posted-In: News


Related Articles (TGX)

View Comments and Join the Discussion!

Partner Center